Calyxo Marks One Year of 2nd-Gen CVAC System at AUA 2025
Calyxo, Inc., a medical device company revolutionizing kidney stone treatment, is marking the one-year anniversary of its second-generation CVAC System at the American Urological Association (AUA) 2025 Annual Meeting, held April 26–29 in Las Vegas. The company will highlight this milestone by presenting new clinical data and hosting educational sessions aimed at sharing insights and advancing the standard of care for kidney stone patients.
Calyxo’s CVAC System, a key component of the Steerable Ureteroscopic Renal Evacuation (SURE) procedure, has now been used to treat more than 10,000 patients. Since its launch at AUA 2024, the second-generation device has seen rapid adoption among urologists for its ability to improve stone clearance and reduce the need for multiple procedures.
Addressing an Urgent Clinical Need
Kidney stones affect roughly 10% of the U.S. population, often causing intense pain and repeated interventions. Traditional treatments may require multiple sessions, leading to increased healthcare costs and greater patient burden. Calyxo aims to change that narrative.
“Kidney stones are not only painful but frequently require multiple procedures, leading to increased patient discomfort, cost, and risk,” said Jee Shin, Founder of Calyxo. “The second-generation CVAC System has been rapidly embraced by urologists because it aligns with their goal of achieving stone-free outcomes in a single procedure. The data we’re presenting at AUA 2025 reflects our continued commitment to building robust clinical evidence for aspiration-based stone clearance.”
Advancing Stone Removal Technology
The second-generation CVAC System, which received FDA clearance in February 2024, is a fully integrated device that combines microjet irrigation, simultaneous fluid flow, and a large outflow lumen with direct visualization. This unique combination enhances the physician’s ability to efficiently remove stone fragments during and after laser lithotripsy.
In the ASPIRE trial, a multicenter randomized study, the CVAC System demonstrated superior outcomes compared to traditional ureteroscopy (URS), showing significantly lower residual stone volume (RSV) regardless of the initial stone size. Patients treated with the CVAC System also had fewer emergency department visits, hospitalizations, and retreatments one year post-procedure—highlighting its long-term impact on both clinical and economic outcomes.
Expert Endorsement
“When patients seek care, their number one goal is to be stone-free, ideally in one procedure,” said Dr. Roger Sur, Director of the Comprehensive Kidney Stone Center at UC San Diego Health. “The CVAC System offers significantly higher clearance rates and gives urologists greater confidence in achieving that goal. It’s exciting to see a technology that not only improves safety and efficacy but also enhances the overall patient experience.”
Scientific Presence at AUA 2025
Calyxo will be a prominent participant at AUA 2025, with at least eight abstracts accepted for presentation and multiple peer-to-peer learning opportunities. Highlights include:
Scientific Presentations:
- April 26:
- Real-World Experience with CVAC 2.0 (7:40 AM, Marco Polo 805)
- Impact on Intrarenal Pressure (8:04 AM, Marco Polo 805)
- Consistent Low Pressure with Continuous Flow (3:30 PM, Marco Polo 701)
- Retrospective Stone Clearance Analysis and Quantitative Stone Analysis Software Outcomes (3:30 PM, Marco Polo 701)
- April 27:
- Early Experience with Next Gen 2.0 and Quantitative CT (9:30 AM, Marco Polo 701)
- April 28:
- Comparative Study with Ureteric Access Sheath (1:00 PM, Cassanova 505)
- Automated vs. Semi-Automated Volume Measurement (3:30 PM, Cassanova 501)
Educational Events:
- Tech Talks at Booth #1146:
- Suction is Not Enough (April 26, 11:30 AM)
- The Science of Aspiration (April 27, 1:00 PM)
- Plenary Session – Semi-Live Procedures:
- Precision Aspiration with CVAC (April 27, 2:30 PM, Venetian Ballroom)
- Resident BioSkills Lab: Hands-on training session (April 27, 4:00 PM; registration required)
- In-Booth Demos: April 26–28, 10:30 AM–4:00 PM at Booth #515 (by appointment)
About Kidney Stones
Kidney stones represent a significant clinical burden, with U.S. healthcare costs projected to reach $4.1 billion annually by 2030, according to Current Urology Reports. Delays in treatment, repeat procedures, and complications make the need for more effective technologies urgent.
About the CVAC System
The CVAC System is a minimally invasive device engineered to enhance kidney stone removal through a combination of vacuum aspiration and irrigation-based clearance. Its innovative design supports the goal of single-procedure success and reduces residual fragments that often lead to complications and follow-up surgeries.
About Calyxo, Inc.
Calyxo, Inc. is a Silicon Valley-based medical device company committed to improving kidney stone treatment through innovative, minimally invasive solutions. The company is focused on empowering urologists with tools that improve efficiency, safety, and outcomes for patients worldwide.
